NashBio’s diverse, rich dataset can be utilized to discover novel drug targets, particularly for conditions like neuropathic pain that are best understood using real-world clinical data. Paired with our significant technical and clinical knowledge, we help clients improve their early stage drug discovery.
Identifying drug targets for pain relief
Identifying drug targets for pain relief
Overview
Challenge
Genome-wide association studies (GWAS) reveal genes and molecular pathways that impact diseases and medical conditions, which are critical to identifying novel drug targets. Some conditions require detailed information that is best defined using real-world medical data. For example, pain associated with neuropathies is difficult to measure given the personal subjectivity of pain, but can be stratified by dosage of pain medications from electronic health records (EHRs).
NashBio was contracted to utilize our robust dataset to define variants associated with neuropathic pain, and potentially generalized pain more broadly.
At a Glance
97
MEGAEX genotypes
11
median length of genomic patient EHR
1
neurology patients
Drug discovery
target identification
Our Impact
Our multimodal data and clinical expertise made NashBio uniquely-suited to identify novel genetic factors for complex conditions like pain. We offer enriched, longitudinal real-world EHR data that is critical for studying neuropathy-associated pain, given that neuropathies worsen with age.
Using our technical expertise of the data and clinical workflow, we refined a cohort using several diagnostic codes and unstructured notes, resulting in more robust GWAS analyses when paired with associated genomic data that we offer (WGS, array).
Since a significant percentage of our participants have been historically underrepresented in medical research, it’s more likely to identify novel drug targets relative to other datasets. Importantly, our genetic and phenotypic data improves early stage research into molecular targets for drug development.
NashBio Differentiators
Curated Real World Data
Demographically Diverse
Multimodal & Multi-Omic Data
Our Impact
Our multimodal data and clinical expertise made NashBio uniquely-suited to identify novel genetic factors for complex conditions like pain. We offer enriched, longitudinal real-world EHR data that is critical for studying neuropathy-associated pain, given that neuropathies worsen with age.
Using our technical expertise of the data and clinical workflow, we refined a cohort using several diagnostic codes and unstructured notes, resulting in more robust GWAS analyses when paired with associated genomic data that we offer (WGS, array).
Since a significant percentage of our participants have been historically underrepresented in medical research, it’s more likely to identify novel drug targets relative to other datasets. Importantly, our genetic and phenotypic data improves early stage research into molecular targets for drug development.
Nashbio Differentiators
Curated Real World Data
Demographically Diverse
Multimodal & Multi-Omic Data
Defining disease outcomes using real-world data
Improving AI-guided clinical decision support
Developing predictive diagnosis algorithms
Data Solutions with
Your Goals in Mind
Let us help you get the exact data you need so you can advance novel discoveries, streamline operations and increase speed to market.
